Suppr超能文献

用抗胸腺细胞球蛋白(ATG)治疗难治性韦格纳肉芽肿:15例患者的开放性研究。

Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients.

作者信息

Schmitt Wilhelm H, Hagen E Christiaan, Neumann Irmgard, Nowack Rainer, Flores-Suárez Luis Felipe, van der Woude Fokko J

机构信息

Fifth Department of Medicine, University Hospital Mannheim of the University of Heidelberg, Mannheim, Germany.

出版信息

Kidney Int. 2004 Apr;65(4):1440-8. doi: 10.1111/j.1523-1755.2004.00534.x.

Abstract

BACKGROUND

A subset of patients with Wegener's granulomatosis does not respond sufficiently to cyclophosphamide and glucocorticosteroids or suffers of intolerable side effects. Anecdotal data suggest that antithymocyte globulin (ATG) may be a treatment option for these patients. We now describe 15 patients treated with ATG for refractory Wegener's granulomatosis.

METHODS

Fifteen patients with histologically proven active refractory Wegener's granulomatosis (seven unresponsive to cyclophosphamide, eight intolerant) were treated with ATG by a protocol (SOLUTION protocol) designed by the European Vasculitis Study (EUVAS) Group.

RESULTS

Before ATG administration, patients had received a mean of 5.2 (range 2 to 7) different therapeutic approaches including glucocorticosteroids and cyclophosphamide in all and experimental therapies in six, without control of disease activity [2.8 (range 1 to 7) relapses during a disease duration of 63.2 (range 18 to 180) months]. Thirteen of 15 patients showed a favorable response to ATG with partial (N= 9) or complete (N= 4) remission. During a follow-up of 21.8 (range 6 to 68) months, seven patients relapsed after a mean of 8.4 (range 2 to 24) months (five minor and two major relapses). Six patients are free of relapse for 22.3 (range 7 to 64) months. Two patients died, 1 and 3 days following the first dose of ATG, due to pulmonary hemorrhage and infection (one each). Although further immunosuppressive treatment was required in all surviving patients, a less intensive regimen could be applied in 12. Beside fever and chills associated with the first gift of ATG, ATG was well tolerated, with infections being observed in five cases and serum sickness in two.

CONCLUSION

Anti-T-cell-directed treatment with ATG may be a therapeutic option for severe refractory Wegener's granulomatosis if simultaneous infections and fluid overload have been ruled out. In patients with alveolar hemorrhage, ATG should only be used under special caution.

摘要

背景

一小部分韦格纳肉芽肿患者对环磷酰胺和糖皮质激素反应不佳或出现难以耐受的副作用。轶事数据表明,抗胸腺细胞球蛋白(ATG)可能是这些患者的一种治疗选择。我们现在描述15例接受ATG治疗难治性韦格纳肉芽肿的患者。

方法

15例经组织学证实为活动性难治性韦格纳肉芽肿的患者(7例对环磷酰胺无反应,8例不耐受),按照欧洲血管炎研究(EUVAS)小组设计的方案(SOLUTION方案)接受ATG治疗。

结果

在给予ATG之前,患者平均接受了5.2种(范围2至7种)不同的治疗方法,包括所有患者均接受糖皮质激素和环磷酰胺治疗,6例患者接受了实验性治疗,但疾病活动未得到控制[在63.2个月(范围18至180个月)的病程中复发2.8次(范围1至7次)]。15例患者中有13例对ATG表现出良好反应,部分缓解(N = 9)或完全缓解(N = 4)。在21.8个月(范围6至68个月)的随访中,7例患者在平均8.4个月(范围2至24个月)后复发(5例轻度复发和2例重度复发)。6例患者在22.3个月(范围7至64个月)内无复发。2例患者在首次给予ATG后1天和3天死亡,分别死于肺出血和感染。尽管所有存活患者都需要进一步的免疫抑制治疗,但12例患者可以采用强度较低的治疗方案。除了与首次给予ATG相关的发热和寒战外,ATG耐受性良好,观察到5例感染和2例血清病。

结论

如果排除了同时存在的感染和液体超负荷,用ATG进行抗T细胞治疗可能是重度难治性韦格纳肉芽肿的一种治疗选择。对于肺泡出血患者,使用ATG时应格外谨慎。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验